

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) hereby announces that Ms. WONG Sau Ping (“**Ms. Wong**”) has tendered her resignation as one of the joint company secretaries and an authorised representative of the Company (“**Authorised Representative**”) under Rule 3.05 of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 30 August 2018. Ms. Wong has confirmed that she has no disagreement with the Board in any respect and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that Ms. LEUNG Suet Lun (“**Ms. Leung**”) has been appointed as one of the joint company secretaries of the Company and the Authorised Representative in place of Ms. Wong with effect from 30 August 2018. Ms. KO Wing Yu (“**Ms. Ko**”) will remain as the other joint company secretary of the Company.

The Stock Exchange has granted a waiver (the “**Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period from the date of appointment of Ms. Leung as the joint company secretary to 9 March 2019 (the “**New Waiver Period**”) in relation to the eligibility of Ms. Ko to act as a joint company secretary of the Company on the conditions that:

- (i) Ms. Ko will be assisted by Ms. Leung during the New Waiver Period;
- (ii) the Company should notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation, with the expectation that, after the end of the New Waiver Period, the Company will be able to demonstrate that Ms. Ko can satisfy Rule 3.28 of the Listing Rules after having the benefit of Ms. Leung’s assistance such that a further waiver will not be necessary; and

(iii) the Company will announce details of the Waiver, including its reasons and conditions.

The Waiver will be revoked immediately if and when Ms. Leung ceases to provide assistance to Ms. Ko.

Ms. Leung, a manager of the Listing Services Department of TMF Hong Kong Limited (a global corporate service provider), has over 10 years of professional experience in legal, company secretarial and tax consulting fields. She is a member of the Hong Kong Institute of Certified Public Accountants and a solicitor of Hong Kong.

The Board would like to take this opportunity to thank Ms. Wong for her contributions during her tenure of services and extend a warm welcome to Ms. Leung on her new appointment.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 30 August 2018

As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Chow Siu Lui, Mr. Wang Qing and Mr. Liu Wenfang.